471-480 of 575 results for 'consumer data right'

A growing tide? Climate change class action proceedings issued against the Federal Treasury
Insight 12 Aug 2020

Australia is becoming front and centre as a forum for activist climate change litigation against corporates, financial institutions and government. We assess the significance of these proceedings and outline the key questions your organisation and its Board should be asking. ...

Dollars and sense: the evolution of executive remuneration practices
Insight 30 Sep 2020

The need for robust executive remuneration frameworks is becoming increasingly important as companies tackle the challenges arising out of the COVID-19 pandemic, a heightened regulatory environment and the need to strike the right balance with executives to drive and reward conduct and performance t ...

Changes to open and transparent sale process requirement for foreign persons acquiring agricultural land
Insight 22 Oct 2018

On 25 September 2018 the Foreign Investment Review Board released revised guidance on the application of the requirement for an open and transparent sale process for foreign persons acquiring agricultural land Partner Wendy Rae Senior Associate Julian Barendse and Lawyer Bianca Sacco examine these ...

Regulatory scrutiny of private capital increases
Insight 28 Feb 2025

Private capital is becoming a growing focus of regulators, both in Australia and internationally, given the ever-increasing flow of capital to the sector in recent years. ...

Interlocutory injunction refused based on 'doubtful' patent term extension
Insight 23 Feb 2022

In the fight against patent infringement, challenging the validity of patent term extensions (PTEs) is increasingly becoming the weapon of choice for generic pharmaceutical companies. Since around the mid-2000s, patentees in pharmaceutical patent cases have typically been successful in bids for interlocutory injunctions, aiming to prevent the launch of generic products in Australia. The recent Biogen decision by the Federal Court is the latest in a trend of refusing interlocutory injunctions, and a clear indication the tide is turning. ...

New ASIC guidance on how superannuation and managed funds can avoid 'greenwashing'
Insight 16 Jun 2022

Greenwashing in the promotion of managed investment and superannuation funds is one of ASIC's current corporate governance priorities as it continues to 'monitor the market … looking for misleading claims about ESG and sustainability'. ...

The ASX Listing Rules up for review but still fit for purpose: the case for retaining the existing policy settings on reverse takeovers
Insight 13 Oct 2025

Merger transactions without a vote of the shareholders of each merger party are back in the headlines as a second deal sparks fresh tension and mounting calls from the Australian investment community ...

World first: Australia says ‘yes’ to AI inventors
Insight 30 Jul 2021

The decision in Thaler v Commissioner of Patents [2021] FCA 879 is the first judicial determination in the world in favour of AI systems being named as inventors of a patent. The availability of patent protection for AI-generated inventions is a vexed and controversial issue. ...

Nucleus – corporate law developments: major FIRB law changes; ASIC extends relief for financial reporting and AGM requirements; and other corporate law developments
Insight 08 Feb 2021

Major foreign investment law changes; ASIC extends relief for financial reporting and AGM requirements and issues guidance on design and distribution laws; ASX issues guidance to address 'earning surprises'; ACCC releases first digital platform inquiry interim report; and WA Supreme Court hands down decision with implications for legal professional privilege in internal emails. ...

Patent term extensions under siege: a new era of challenges for pharmaceutical patentees
Insight 24 Nov 2024

A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...

Refine